Pharmacyclics Inc

Pharmacyclics — Technical Presentation (December 2013)

22 slides from Pharmacyclics's technical presentation, Dec 11, 2013

  1. Slide 1: Ibrutinib in combination with rituximab (iR) is well tolerated in high-risk CLL

    Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk CLL: new, updated results of a Phase II trial in 40 patients. Jan A. Burger’, Michael J. Keating’, William G. Wierda’, Julia Hoellenriegel’, Ghayathri Jeyakumar’, A

  2. Slide 2: z | cae Alpaents a ES a

    > 2 3 & go z | cae Alpaents 3 a ES 4 a i a ce te 2 : Ss be i i ; $ » 8 » & » a a 3 i b b induces high rates o = re die espo e previo [SEEPRRERENTOTOT TTT I Month Compete response pl pri sponte 2 Pail eigenen hgh x Patents wih a Response (4) Tian Month

  3. Slide 3: Objectives

    OBJECTIVES * Hypothesis: addition of rituximab to ibrutinib accelerates responses and increases ORR in high-risk CLL » Assess activity of ibrutinib and rituximab combination therapy (iR) in high-risk CLLISLL * Assess the tolerability of the combination of ibrutinib and rituximab in CLL/SLL

  4. Slide 4: Eligibility

    ELIGIBILITY »* Previously treated high-risk CLL (del17p, del11q, short [<3 years] remission after CIT) * Patients with 17p deletion or TP53 mutation are not required to have received prior therapy * Treatment indication by 2008 IWCLL Criteria » Adequate renal and hepatic function

  5. Slide 5: Patient Characteristics (I)

    PATIENT CHARACTERISTICS (I) Median Range Age (years) 65 (35-82) 82M (mg/L) 4.15 (2.2-12) WBC (x102/uL) 22.35 (2.2-298) ALC (x103/uL) 19,924 (377-276,954) # prior treatments 2.5 (0 -8)* *4 previously untreated pt with del17p, TP53 mutation

  6. Slide 6: Patient Characteristics (II)

    PATIENT CHARACTERISTICS (Il) N % Rai stage Wil 714 18/10% Il 6 15% lV 23 58% FISH 47p 20 50% cytogenetics 11q 13 33% 13q 5 13% Neg 2 5% IGHV mutational Mutated 1 3% status Unmutated 32 80% Not Done 7 18%

  7. Slide 7: Ibrutinib and Rituximab (iR) in High-Risk CLL

    IBRUTINIB AND RITUXIMAB (IR) IN HIGH-RISK CLL Rituximab Wiieonaid Month 7-12 (375 mg/m2) Day Cycle Ibrutinib 420 mg/d PO once daily Patients with benefit after 12 cycles willbe allowed to continue on single-agent ibrutinib

  8. Slide 8: oO /25%-75%

    oO /25%-75% 8 9 101 12 13 14 15 16

  9. Slide 9: m Median

    m Median 25%-75% Non-Outlier Range

  10. Slide 10: @ Median

    @ Median [25%-75% Non-Outlier Range ne25 Startofi*Month 2 3 4 6 7 8 Ss 10 11:12 13 14 15 16 SS Time (months)

  11. Slide 11: Changes in bone marrow infiltration during iR therapy

    Changes in bone marrow infiltration during iR therapy 40 After 12 months hh I] B00 | | | | -40 BB others -80 n=33 p< 0.005 ~ P< 0.00001 p< 0.00001 z= ry 2 g 2 6 5 a = a Difference in Lymphocytes in BM [%]

  12. Slide 12: CT Assessment at Months

    CT ASSESSMENT AT 12 MONTHS: Lymph node sites (34 evaluable patients) 0 3 2) 30 5 = S 50 60 70 80 90 WB others 400 Average decrease in LN size [%]

  13. Slide 13: Best Response (N=40)

    BEST RESPONSE* (N=40) N % CR# 4 10 PR 34 85 ORR 37 95 NR 2 5 *At 12 months or best response before study discontinuation #MRD-negative: 1/4, MRD level: 0.1, 0.2, 0.1%

  14. Slide 14: Progression-free survival: all patients, Del 17p versus others

    All patients Del 17p versus others || Median PFS at “| Median PFS at <"| 18months: i 48 months: 78% i... Del17p: 72% = Others: 84% 0.00. aon mae 024 6 be a em mm SE a)

  15. Slide 15: Overall survival: all patients, Del 17p versus others

    All patients Del 17p versus others Median PFS at 18 months: OS at Proportion Surviving & . 0; 48 months: 84 % Delt7p: 78% os} Others: 89% wan 000: 0004 777" alll

  16. Slide 16: Toxicities during iR therapy

    # of cases Toxicities during iR therapy BE Grade1 12 O crade2 t | Grade3 6 4 i ili by é Li a ORT P58 CSS 4 see ae Sou Poses Sy 2 COSINE Se Sloe” Sos EROS SO SSA SG PRS se Fr Wis RO S ee Poe F SOO SSE YS ve RS Oe « s é . ¥ é g £ Ss < Related Unrelated

  17. Slide 17: Causes of Study Discontinuation (N=9)

    CAUSES OF STUDY DISCONTINUATION (N=9) Patient #) Age, FISHCG, | Onstudy | Reason for dis- Best Cause of gender |hierarchical| (# of continuation | response death (M/F) cycles) Death in |Unknown (passed| 4 69, M 41g 15 remission PR laway in his sleep) Progressive Pneumonia, 36, F 11q 6 disease PR sep

  18. Slide 18: t ay

    i 4 i a is F t ay é + tee we one asin — Raa HRT OORT [aw GE 7 fe) Mean KG (sd)_| sd) | =t0 (sa) B02 (238) Peaos

  19. Slide 19: Before weeks months

    Before 2 weeks 9 months ibrutinib+R (iR) iR iR

  20. Slide 20: Correlative studies: GEP

    Correlative studies: GEP (witnetena Hartmann, Andreas Rosenwald, Wuerzburg U, Germany) CLL during iR therapy CLL in NLC co-culture™ *Burger JA et al. Blood 113: 3050-8, 2009 Down-regulation of BCR and NFxB target genes during iR therapy

  21. Slide 21: Summary

    SUMMARY * Ibrutinib plus rituximab (iR) has profound activity in high-risk CLL * High ORR (>90%), 10% CR, favorable toxicity profile, improvement in bone marrow infiltration and function * Addition of rituximab accelerates ibrutinib response in CLL » Well tolerated, associated with improvement in QO

  22. Slide 22: Collaborators and funding

    LEUKEMIA& LYMPHOMA SOCIETY fighting blood cancers Collaborators: * Wiirzburg University, Germany: A Rosenwald, E Hartmann * CLLGRF: F Caligaris-Cappio, N Chiorazzi, Z Estrov, N Kay * MDACC: M Keating, W Wierda, S O’Brien, H Kantarjian, V Gandhi, A Ferrajoli, K Balakrishnan # UCSD: T Kipps My laborat

Pharmacyclics — Technical Presentation (December 2013) on 6ix